The FDA's approvals database lists a supplement approved for the intravitreal dexamethasone implant (Ozurdex) under NDA 022315. The record does not describe what the supplement changed.
The product is an ophthalmic implant used for retinal conditions; it reached this desk through the regulatory sweep but has no direct respiratory indication. Supplements typically cover labelling or manufacturing changes.
For pulmonologists, there is nothing to act on.
- FDA approved a supplement for an intravitreal dexamethasone implant
- The public record does not state what changed
- The product is ophthalmic and has no respiratory indication
- No change in respiratory prescribing follows
Why it matters
Separating administrative regulatory entries from safety signals keeps attention on what matters.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free